Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 4/20 | 0.53 |
| ▸ | BCR | P11274 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347641 | 0.91 | ABL1 (0.62) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5357407 | 0.88 | ABL1 (0.56) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5351819 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5344234 | 0.85 | ABL1 (0.56) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5355726 | 0.84 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5343338 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5346607 | 0.83 | ABL1 (0.56) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5344061 | 0.83 | ABL1 (0.56) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5344003 | 0.83 | ABL1 (0.53) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 | |
| SCHEMBL5355746 | 0.83 | ABL1 (0.53) | CYP1A2CYP2D6CYP3A4CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007507531-A | — | — | 2007-03-29 | — | — | JP | claimed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | claimed |
| EP-1670771-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-06-21 | — | — | EP | claimed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | claimed |
| WO-2005033086-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-14 | — | — | WO | claimed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | ERBB2, ERBB3, ERBB4 | CYP1A2 4477/4885CYP2D6 4609/4885CYP3A4 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.